Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma

Trial Profile

Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs DNX 2440 (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 26 Nov 2018 According to Alcyone Lifesciences media release, the first patient was treated with DNAtrix's DNX-2440.
    • 26 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top